Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. It has about one year in cash. Last year, it spent $3.5M in R&D and these costs are set to increase as it…
Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) had its stock coverage assumed at Goldman Sachs Group Inc (NYSE:GS). The firm assigned buy rating on the stock. That positive rating of the stock came hot on the heels of the upgrade from Zacks, where analysts at Zacks assigned neutral on the stock from underperform. Companhia Energetica Minas…
BlackBerry (BBRY, BB.TO) reported a Q4 adjusted loss of $0.08 per share, better than expectations of a loss of $0.54 per share, if comparable. Revenue was $976 million, down 64% from $2.7 billion in the year ago quarter, and below the analyst consensus of $1.2 billion on Capital IQ. During Q4, the company recognized hardware…
U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the…
NovaBay Pharmaceuticals (NYSEMKT:NBY) is lower in late trading after the clinical-stage biopharmaceutical company said late Wednesday that it intends to offer shares of its common stock and warrants in an underwritten public offering. Shares are down 8.73% at $1.15, with a 52-week range of $0.76 – $2.03. The company intends to use the net proceeds…
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for…
